THE BRITISH ASSOCIATION OF DERMATOLOGISTS
HomeContactLegalLinksSite MapHistorySpecialist GroupsMembersArchiveResearch 
Public InformationClinical ServicesEducationClinical StandardsConferences and EventsMediaSAS Doctors
Patient Information and Leaflets
What is a Dermatologist
About the Skin
Skin Cancer
Information about Dermatology Services
Patient Support Groups
Frequently Asked Questions
Information about your health rights

Search Site
Enter Text

Member Login
If you are a member, please log in below
Username:
Password:
     
 |  Forget Password
 
>> Efalizumab

ATTENTION:

The European Medicines Agency (EMEA) has come to the decision that the risks of Raptiva (Efalizumab) outweigh its benefits and that the marketing authorisation for this medicine should be suspended in the EU. Therefore the British Association of Dermatologists have decided to remove the Efalizumab Patient Information Leaflet. For more information, please visit the EMEA website for their press release:

www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf
Psoriasis and Psoriatic Arthritis Alliance
 
 
 
web master
©2008 British Association of Dermatologists